1. Phase II evaluation of VP 16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer;Ahmann;Cancer Treat. Rep.,1976
2. Podphyllotoxin derivate VP 16-213;Arnold;Cancer Chemother. Pharmacol.,1979
3. Bender, R. A., Anderson, T., Fisher, R. T. et al. (in press) The activity of the epipodophyllotoxin VP 16 in the treatment of combination chemotherapy resistant non-Hodgkin's lymphoma. Am. J. Hematol.
4. The use of an epipodophyllotoxin derivative (VP 16-213) in the treatment of acute monocytic leukaemias;Bernasconi,1976
5. Mono- and combination chemotherapy with VP 16-213 in small cell lung cancer (SCL);Brunner,1979